NASDAQ:ABMDABIOMED Stock Price, Forecast & News

ABIOMED's stock was trading at $151.13 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ABMD stock has increased by 102.0% and is now trading at $305.35.
View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for ABIOMED.

ABIOMED is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for ABIOMED.

ABIOMED will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

ABIOMED, Inc. (NASDAQ:ABMD) posted its quarterly earnings data on Thursday, April, 30th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by $0.26. The medical equipment provider earned $206.66 million during the quarter, compared to analyst estimates of $209.58 million. ABIOMED had a return on equity of 18.51% and a net margin of 24.14%. The company's quarterly revenue was down .2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.60 EPS.
View ABIOMED's earnings history.

8 brokerages have issued 12 month target prices for ABIOMED's shares. Their forecasts range from $152.00 to $240.00. On average, they expect ABIOMED's share price to reach $193.00 in the next year. This suggests that the stock has a possible downside of 36.8%.
View analysts' price targets for ABIOMED.

News stories about ABMD stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. ABIOMED earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the next few days.
View the latest news about ABIOMED.

ABIOMED saw a decline in short interest in June. As of June 30th, there was short interest totaling 2,360,000 shares, a decline of 13.6% from the June 15th total of 2,730,000 shares. Based on an average trading volume of 559,700 shares, the short-interest ratio is presently 4.2 days. Currently, 5.4% of the company's shares are short sold.
View ABIOMED's Current Options Chain.

Some companies that are related to ABIOMED include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Stryker (SYK), Boston Scientific (BSX), Edwards Lifesciences (EW), DexCom (DXCM), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), Hologic (HOLX), Teleflex (TFX), Varian Medical Systems (VAR) and Steris (STE).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Align Technology (ALGN), Netflix (NFLX), Arista Networks (ANET), Square (SQ), Paypal (PYPL), salesforce.com (CRM) and Adobe (ADBE).

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

ABIOMED's stock is owned by a number of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.53%), Villere ST Denis J & Co. LLC (0.51%), Marathon Asset Management LLP (0.33%), Scout Investments Inc. (0.27%), Country Trust Bank (0.25%) and Rhenman & Partners Asset Management AB (0.15%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Martin P Sutter and Michael G Howley.
View institutional ownership trends for ABIOMED.

ABMD stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Assenagon Asset Management S.A., Chicago Capital LLC, Retirement Systems of Alabama, Oregon Public Employees Retirement Fund, Country Trust Bank, Zurcher Kantonalbank Zurich Cantonalbank, and Optimal Asset Management Inc.. Company insiders that have sold ABIOMED company stock in the last year include David M Weber, and Dorothy E Puhy.
View insider buying and selling activity for ABIOMED.

ABMD stock was acquired by a variety of institutional investors in the last quarter, including Scout Investments Inc., Villere ST Denis J & Co. LLC, Sumitomo Mitsui Trust Holdings Inc., Marathon Asset Management LLP, UBS Group AG, West Coast Financial LLC, Pacer Advisors Inc., and First Trust Advisors LP.
View insider buying and selling activity for ABIOMED.

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ABMD stock can currently be purchased for approximately $305.35.

ABIOMED has a market capitalization of $13.75 billion and generates $840.88 million in revenue each year. The medical equipment provider earns $203.01 million in net income (profit) each year or $4.74 on an earnings per share basis. ABIOMED employs 1,536 workers across the globe.

The official website for ABIOMED is www.abiomed.com.

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]